Cross-Reactivity of Schistosoma mansoni Cytosolic Superoxide Dismutase, a Protective Vaccine Candidate, with Host Superoxide Dismutase and Identification of Parasite-Specific B Epitopes

ABSTRACT Schistosoma mansoni, an intravascular parasite, has evolved a number of immune evasion mechanisms to establish itself in the host, such as antioxidant enzymes. Our laboratory has demonstrated that the highest levels of certain antioxidant enzymes are found in adult worms, which are the least susceptible to immune killing. Vaccination of mice with naked DNA constructs containing the gene encoding Cu/Zn cytosolic superoxide dismutase (SmCT-SOD) showed significant levels of protection compared to a control group, and our data demonstrate that the adult worms are a target of the immune response that confers resistance in SmCT-SOD DNA-vaccinated mice. Because SmCT-SOD shows significant identity with the human homologue, we evaluated the reactivity of anti-SmCT-SOD antibodies derived from SmCT-SOD-immunized mice and rabbits and from S. mansoni-infected individuals to human superoxide dismutase (hSOD) and SmCT-SOD parasite-specific peptides to assess the potential for autoimmune responses from immunization with the recombinant molecule. In addition, we evaluated the ability of various SmCT-SOD adjuvant-delivered immunizations to induce cross-reactive antibodies. Both mouse and rabbit antibodies generated against SmCT-SOD recognized the denatured form of hSOD. The same antibodies did not recognize nondenatured hSOD. Sera from infected individuals with different clinical forms of schistosomiasis recognized SmCT-SOD but not hSOD. Antibodies from mice immunized with different SmCT-SOD-containing formulations of both DNA and protein were able to recognize SmCT-SOD-derived peptides but not soluble hSOD. All together, these findings serve as a basis for developing a subunit vaccine against schistosomiasis.

[1]  D. Taylor Schistosome vaccines , 2005, Experientia.

[2]  P. LoVerde,et al.  Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes. , 2003, Vaccine.

[3]  J. Ježek,et al.  Differences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase. , 2003, Vaccine.

[4]  T. Nutman,et al.  Class and subclass selection in parasite-specific antibody responses. , 2003, Trends in parasitology.

[5]  Hongfan Sun,et al.  Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. , 2003, Vaccine.

[6]  J. Brewer,et al.  Interleukin‐18 plays a role in both the alum‐induced T helper 2 response and the T helper 1 response induced by alum‐adsorbed interleukin‐12 , 2003, Immunology.

[7]  N. R. Bergquist Schistosomiasis: from risk assessment to control. , 2002, Trends in parasitology.

[8]  Edward J. Pearce,et al.  The immunobiology of schistosomiasis , 2002, Nature Reviews Immunology.

[9]  D. Colley,et al.  Practical and ethical issues in the development of a vaccine against schistosomiasis mansoni. , 2002, The American journal of tropical medicine and hygiene.

[10]  D. Volkin,et al.  Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. , 2002, Journal of pharmaceutical sciences.

[11]  M. Patarroyo,et al.  Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. , 2002, Vaccine.

[12]  M. L. Mackichan,et al.  Recent developments in adjuvants for vaccines against infectious diseases. , 2001, Biomolecular engineering.

[13]  T. Wynn,et al.  Defining a schistosomiasis vaccination strategy - is it really Th1 versus Th2? , 2000, Parasitology today.

[14]  L. Chitsulo,et al.  The global status of schistosomiasis and its control. , 2000, Acta tropica.

[15]  R. Corrêa-Oliveira,et al.  Natural versus drug-induced resistance in Schistosoma mansoni infection. , 2000, Parasitology today.

[16]  M. Sabel,et al.  In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. , 2000, Cancer research.

[17]  Brito,et al.  CD4+ T Cells of Schistosomiasis Naturally Resistant Individuals Living in an Endemic Area Produce Interferon‐γ and Tumour Necrosis Factor‐α in Response to The Recombinant 14kdaSchistosoma mansoni Fatty Acid‐Binding Protein , 2000, Scandinavian journal of immunology.

[18]  M. Michalak,et al.  Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization , 2000, Clinical and experimental immunology.

[19]  Virander S. Chauhan,et al.  Analysis of Immune Responses against T- and B-Cell Epitopes fromPlasmodium falciparum Liver-Stage Antigen 1 in Rodent Malaria Models and Malaria-Exposed Human Subjects in India , 2000, Infection and Immunity.

[20]  C. Hunter,et al.  Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. , 1999, Journal of immunology.

[21]  O’Hagan,et al.  Microparticles and polymers for the mucosal delivery of vaccines. , 1998, Advanced drug delivery reviews.

[22]  P. LoVerde Do antioxidants play a role in schistosome host-parasite interactions? , 1998, Parasitology today.

[23]  C. A. Santos,et al.  Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model , 1998, Cancer Immunology, Immunotherapy.

[24]  Scott D. Putney,et al.  Improving protein therapeutics with sustained-release formulations , 1998, Nature Biotechnology.

[25]  A. Butterworth Immunological aspects of human schistosomiasis. , 1998, British medical bulletin.

[26]  N. R. Bergquist Schistosomiasis vaccine development: progress and prospects. , 1998, Memorias do Instituto Oswaldo Cruz.

[27]  A. Deelder,et al.  Anti-schistosome IgG4 and IgE at 2 years after chemotherapy: infected versus uninfected individuals. , 1997, The Journal of infectious diseases.

[28]  P. LoVerde,et al.  Schistosoma mansoni: the developmental regulation and immunolocalization of antioxidant enzymes. , 1997, Experimental parasitology.

[29]  Donald E. Chickering,et al.  Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.

[30]  J. Schwartz,et al.  Expression and characterization of glutathione peroxidase activity in the human blood fluke Schistosoma mansoni , 1996, Infection and immunity.

[31]  A. Simpson,et al.  Evidence that cellular immune responses to soluble and membrane associated antigens are independently regulated during human schistosomiasis mansoni , 1996, Parasite immunology.

[32]  P. LoVerde,et al.  Immune response to Schistosoma mansoni phosphoglycerate kinase during natural and experimental infection: identification of a schistosome-specific B-cell epitope , 1995, Infection and immunity.

[33]  H. Okada,et al.  Biodegradable microspheres in drug delivery. , 1995, Critical reviews in therapeutic drug carrier systems.

[34]  D. Engels,et al.  Impact of repeated community-based selective chemotherapy on morbidity due to schistosomiasis mansoni. , 1994, The American journal of tropical medicine and hygiene.

[35]  A. Sher,et al.  Interferon-gamma production by peripheral blood mononuclear cells from residents of an area endemic for Schistosoma mansoni. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[36]  D. Harn,et al.  T and B epitope determination and analysis of multiple antigenic peptides for the Schistosoma mansoni experimental vaccine triose-phosphate isomerase. , 1994, Journal of immunology.

[37]  James Sl,et al.  Immune effector role of macrophages in experimental schistosomiasis mansoni. , 1994 .

[38]  D. Boros,et al.  Immune effector role of macrophages in experimental schistosomiasis mansoni. , 1994, Immunology series.

[39]  E R James,et al.  Superoxide dismutase. , 1994, Parasitology today.

[40]  R. Maizels,et al.  Immunological modulation and evasion by helminth parasites in human populations , 1993, Nature.

[41]  M. Ouattara,et al.  Resistance to Schistosoma mansoni in humans: influence of the IgE/IgG4 balance and IgG2 in immunity to reinfection after chemotherapy. , 1993, The Journal of infectious diseases.

[42]  A. Vashishtha,et al.  Surface-exposed conserved region of the streptococcal M protein induces antibodies cross-reactive with denatured forms of myosin. , 1993, Journal of immunology.

[43]  P. Coulson,et al.  Pulmonary granulomatous hypersensitivity: cell-mediated responses to embolized schistosome larvae and eggs. , 1993, Regional immunology.

[44]  C. Shoemaker,et al.  T and B cell epitope mapping of SM23, an integral membrane protein of Schistosoma mansoni. , 1992, Journal of immunology.

[45]  D. Pritchard,et al.  Immunity to helminths: Ready to tip the biochemical balance? , 1992, Parasitology today.

[46]  M. Hammarskjöld,et al.  Schistosoma mansoni: cloning of a complementary DNA encoding a cytosolic Cu/Zn superoxide dismutase and high-yield expression of the enzymatically active gene product in Escherichia coli. , 1992, Experimental parasitology.

[47]  D. Dunne,et al.  Human immunity to Schistosoma mansoni: observations on mechanisms, and implications for control. , 1992, Immunological investigations.

[48]  A. Capron,et al.  Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection , 1992, European journal of immunology.

[49]  A. Capron,et al.  Effector functions of eosinophils in schistosomiasis. , 1992, Memorias do Instituto Oswaldo Cruz.

[50]  A. Prata,et al.  Evidence for an association between human resistance to Schistosoma mansoni and high anti‐larval IgE levels , 1991, European journal of immunology.

[51]  S. Davis,et al.  Controlled release microparticles for vaccine development. , 1991, Vaccine.

[52]  D. Rahman,et al.  Biodegradable microparticles as controlled release antigen delivery systems. , 1991, Immunology.

[53]  A. Simpson,et al.  Human IgE, IgG4 and resistance to reinfection with Schistosomahaematobium , 1991, Nature.

[54]  R. Prichard,et al.  Schistosoma mansoni: levels of antioxidants and resistance to oxidants increase during development. , 1990, Experimental parasitology.

[55]  M. Wright,et al.  Comparison of the cloned genes of the 26- and 28-kilodalton glutathione S-transferases of Schistosoma japonicum and Schistosoma mansoni. , 1990, Molecular and biochemical parasitology.

[56]  A. Sher,et al.  The human immune response to defined immunogens of Schistosoma mansoni: elevated antibody levels to paramyosin in stool-negative individuals from two endemic areas in Brazil. , 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[57]  D. Boros Immunopathology of Schistosoma mansoni infection , 1989, Clinical Microbiology Reviews.

[58]  R. Damian Molecular mimicry: parasite evasion and host defense. , 1989, Current topics in microbiology and immunology.

[59]  M. Wright,et al.  Molecular and serological characteristics of the glutathione S‐transferases of Schistosoma japonicum and Schistosoma mansoni , 1988, Parasite immunology.

[60]  R. Crouch,et al.  Helminth anti-oxidant enzymes: a protective mechanism against host oxidants? , 1988, Parasitology today.

[61]  R. Prichard,et al.  Antioxidant systems in Schistosoma mansoni: evidence for their role in protection of the adult worms against oxidant killing. , 1988, International journal for parasitology.

[62]  A. Sher,et al.  Mechanisms of immune evasion in schistosomiasis. , 1987, Contributions to microbiology and immunology.

[63]  J. Lambertucci,et al.  Immune responses during human Schistosomiasis mansoni. XI. Immunologic status of patients with acute infections and after treatment. , 1985, Journal of immunology.

[64]  A. Butterworth Cell-mediated damage to helminths. , 1984, Advances in parasitology.

[65]  A. Sher,et al.  Mechanisms of protective immunity against Schistosoma mansoni infection in mice vaccinated with irradiated cercariae III. Identification of a mouse strain, P/N, that fails to respond to vaccination , 1983, Parasite immunology.

[66]  A. Sher,et al.  Mechanisms of protective immunity against Schistosoma mansoni infection in mice vaccinated with irradiated cercariae. IV. Analysis of the role of IgE antibodies and mast cells. , 1983, Journal of immunology.

[67]  A. Sher,et al.  Mechanisms of protective immunity against Schistosoma mansoni infection in mice vaccinated with irradiated cercariae. II. Analysis of immunity in hosts deficient in T lymphocytes, B lymphocytes, or complement. , 1982, Journal of immunology.

[68]  S. T. Haralambides Immunology of parasitic diseases. , 1980 .

[69]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[70]  W. Lang [The immunology of parasitic diseases]. , 1979, MMW, Munchener medizinische Wochenschrift.

[71]  E. Ottesen,et al.  Serological differences between acute and chronic schistosomiasis mansoni detected by enzyme-linked immunosorbent assay (ELISA). , 1979, The American journal of tropical medicine and hygiene.

[72]  D. Colley,et al.  Immune responses during human schistosomiasis mansoni. I. In vitro lymphocyte blastogenic responses to heterogeneous antigenic preparations from schistosome eggs, worms and cercariae. , 1977, International archives of allergy and applied immunology.

[73]  N Katz,et al.  A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. , 1972, Revista do Instituto de Medicina Tropical de Sao Paulo.

[74]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[75]  R. Taylor,et al.  Studies on cyclic passage of yellow fever virus in South American mammals and mosquitoes; marsupials (Metachirus nudicaudatus and Marmosa) in combination with Aedes aegypti as vector. , 1948, The American journal of tropical medicine and hygiene.